Amgen’s Blincyto gets full EU approval for rare leukaemia
admin 20th June 2018 Uncategorised 0European regulators have awarded Amgen’s Blincyto full approval for Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), a rapidly progressing cancer of the blood and bone marrow thought to affect around 900 patients a year in the region.
More: Amgen’s Blincyto gets full EU approval for rare leukaemia
Source: News